TOP2A and cancer: TOP2A positivity, a marker of potential doxorubicin, epirubicin and etoposide benefit,19, 21 was significantly associated with MSI‐H status in all four cancers (epithelial ovarian [p = 0.0018], female genital tract malignancy [p = 0.0011], gastric cancer [p = 0.043] and neuroendocrine tumors [p = 0.0038]).